Sage Therapeutics implements strategic reorganization to support plans for Zurzuvae commercial launch and pipeline advancement

“Our goal is to think big, start small and scale fast as we look to launch Zurzuvae and help women suffering with PPD. Executing on launch and our potential long-term growth catalysts requires us to allocate resources strategically,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “Part of our efforts to become a leaner and stronger company means having to reorganize our workforce. The departing employees contributed so much to our mission and I’m grateful for their incredible dedication to helping patients. Our business fundamentals are strong, we are well capitalized, and our goal is to put Sage in a solid position to optimize commercial execution and develop our pipeline with the goal of significant value creation.” Following a strategic review, the company will: i. Refine pipeline development efforts to advance SAGE-718 and SAGE-324, as well as pause certain earlier-stage programs, with the goal of making evidence-driven investments ii. Implement a ~40% workforce reduction designed to right-size the organization as the company works to achieve sustained growth and allow for commercial hires to support the goal of a successful launch of zurzuvae to treat women with PPD. iii. Align its leadership team structure to scale with pipeline and commercial priorities.